AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2013
May 3, 2013
30583_dirs_2013-05-03_a1510d16-52ad-49c7-8fc4-97678e04fa8b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2013-05-01
Reporting Person: SPIEGELMAN DANIEL K (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-05-01 | Common Stock | M | 28000 | $39.06 | Acquired | 61000 | Direct |
| 2013-05-01 | Common Stock | S | 28000 | $64.4249 | Disposed | 33000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-05-01 | Stock Option (right to buy) | $39.06 | M | 28000 | Disposed | 2022-05-28 | Common Stock (28000) | Direct |
Footnotes
F1: The price in column 4 is a weighted average price. The price actually received ranged from $63.96 to $64.65. The reportng person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.
F3: Original option grant vests 6/48th on November 29, 2012 and 1/48th each on the 29th of each month thereafter.